The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing

Mechanisms of Ageing and Development

Volumn 130, Issue 8, 2009, Pages 497-500

  Testa, Roberto ^a   Bonfigli, Anna Rita ^a   Salvioli, Stefano ^b   Invidia, Laura ^b   Pierini, Michela ^b   Sirolla, Cristina ^a   Marra, Maurizio ^a   Testa, Ivano ^a   Fazioli, Francesca ^a   Recchioni, Rina ^a   Marcheselli, Fiorella ^a   Olivieri, Fabiola ^a   Lanari, Luigi ^a   Franceschi, Claudio ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ageing; Plasminogen activator inhibitor 1; TP53 codon 72 polymorphism

Indexed keywords

ARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLINE; PROTEIN P53;

ADULT; AGE; AGED; AGING; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CODON; FEMALE; GENES, P53; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROLINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650747271     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2009.06.001     Document Type: Article

References (35)

1. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes and consequences. Aterioscler. Thromb. Vasc. Biol. 26 (2006) 2200-2207
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab. Care 27 Suppl. 1 (2004) S5-S10
3. Binder B.R., Mihaly J., and Prager G.W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb. Haemost. 97 3 (2007) 336-342
4. Bonafè M., Barbi C., Storci G., Salvioli S., Capri M., Olivieri F., Valensin S., Monti D., Gonos E.S., De Benedictis G., and Franceschi C. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp. Gerontol. 37 (2002) 1263-1271
5. Bonafè M., Olivieri F., Mari D., Baggio G., Mattace R., Berardelli M., Sansoni P., De Benedictis G., De Luca M., Marchegiani F., Cavallone L., Cardelli M., Giovagnetti S., Ferrucci L., Amadio L., Lisa R., Tucci M.G., Troiano L., Pini G., Gueresi P., Morellini M., Sorbi S., Passeri G., Barbi C., Valensin S., Monti D., Deiana L., Pes G.M., Carru C., and Franceschi C. p53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am. J. Hum. Genet. 65 (1999) 1782-1785
6. Bonafé M., Salvioli S., Barbi C., Trapassi C., Tocco F., Storci G., Invidia L., Tannini I., Rossi M., Marzi E., Misto M., Capri M., Olivieri F., Antonicelli R., Memo M., Uberti D., Nacmias B., Sorbi S., Monti D., and Franceschi C. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ. 11 (2004) 962-973
7. Cesarman-Maus G., and Hajjar K.A. Molecular mechanisms of fibrinolysis. Brit. J. Haematol. 129 (2005) 307-321
8. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., Beach D., and Serrano M. Tumour biology: senescence in premalignant tumours. Nature 436 7051 (2005) 642
9. Comi P., Chiaramonte R., and Maier J.A. Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp. Cell Res. 219 1 (1995) 304-308
10. Declerck P.J., Moreau H., Jespersen J., Gram J., and Kluft C. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb. Haemost. 70 (1993) 858-863
11. Dumont P., Leu J.I., Della Pietra A.C., 3rd, George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (2003) 357-365
12. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21 6 (2003) 1011-1053
13. Fay W.P., Garg N., and Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler. Thromb. Vasc. Biol. 27 6 (2007) 1231-1237
14. Kortlever R.M., and Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 5 23 (2006) 2697-2703
15. Kortlever R.M., Higgins P.J., and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8 8 (2006) 877-884
16. Kunz C., Pebler S., Otte J., and von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23 18 (1995) 3710-3717
17. Levin E.G. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 67 (1986) 1309-1313
18. Martens J.W., Sieuwerts A.M., Bolt-deVries J., Bosma P.T., Swiggers S.J., Klijn J.G., and Foekens J.A. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb. Haemost. 89 (2003) 393-404
19. Miles L.A., Hawley S.B., Baik N., Andronicos N.M., Castellino F.J., and Parmer R.J. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front. Biosci. 10 (2005) 1754-1762
20. Mu X.C., and Higgins P.J. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J. Cell Physiol. 165 (1995) 647-657
21. Myohanen H., and Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. 61 22 (2004) 2840-2858
22. Ørsted D.D., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J. Exp. Med. 204 6 (2007) 1295-1301
23. Pandolfi S., Bonafè M., Di Tella L., Tiberi L., Salvioli S., Monti D., Sorbi S., and Franceschi C. p66(shc) is highly expressed in fibroblasts from centenarians. Mech. Ageing Dev. 126 8 (2005) 839-844
24. Plow E.F., Ploplis V.A., Busuttil S., Carmeliet P., and Collen D. A role of plasminogen in atherosclerosis and restenosis models in mice. Thromb. Haemost. 82 Suppl. 1 (1999) 4-7
25. Salvioli S., Bonafé M., Barbi C., Storci G., Trapassi C., Tocco F., Gravina S., Rossi M., Tiberi L., Mondello C., Monti D., and Franceschi C. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4 (2005) 1264-1271
26. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
27. Shetty S., Shetty P., Idell S., Velusamy T., Bhandary Y.P., and Shetty R.S. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J. Biol. Chem. 283 28 (2008) 19570-19580
28. Sprengers E.D., and Kluft C. Plasminogen activator inhibitors. Blood 69 2 (1987) 381-387
29. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P.J., Smith P., Lu X., and Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 19 (2004) 3328-3337
30. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell Biol. 19 (1999) 1092-1100
31. Tofler G.H., Massaro J., Levy D., Mittleman M., Sutherland P., Lipinska I., Muller J.E., and D'Agostino R.B. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am. J. Cardiol. 96 9 (2005) 1280-1283
32. Van Der Bom J.G., Bots M.L., Haverkate F., Kluft C., and Grobbee D.E. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 101 (2002) 1841-1844
33. West M.D., Shay J.W., Wright W.E., and Linskens M.H. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp. Gerontol. 31 1-2 (1996) 175-193
34. Yamamoto K., Takeshita K., Kojima T., Takamatsu J., and Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc. Res. 66 2 (2005) 276-285
35. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., Tom E., Mack D.H., and Levine A.J. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14 8 (2000) 981-993